newsfilter
← Latest News
GlobeNewswire·

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027